Accessibility Menu
Adma Biologics logo

Adma Biologics

(NASDAQ) ADMA

Current Price$9.22
Market Cap$2.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+7%
5 Year+519%
1 Year-50%
1 Month+15%

Adma Biologics Financials at a Glance

Market Cap

$2.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$509.86M

Net Income (TTM)

$165.35M

EPS (TTM)

$0.68

P/E Ratio

13.51

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$9.22

Volume

71,670

Open

$9.25

Previous Close

$9.22

Daily Range

$9.05 - $9.31

52-Week Range

$7.21 - $20.46

Estimated Earnings Date

Aug 5, 2026

ADMA: Motley Fool Moneyball Superscore

73

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adma Biologics

Industry

Biotechnology

Employees

647

CEO

Adam S. Grossman

Headquarters

Ramsey, NJ 07446, US

ADMA Financials

Key Financial Metrics (TTM)

Gross Margin

61.27%

Operating Margin

40.57%

Net Income Margin

32.43%

Return on Equity

38.97%

Return on Capital

34.36%

Return on Assets

24.86%

Earnings Yield

7.40%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

231.77M

Volume

71.67K

Avg. Volume

5.21M

Financials (TTM)

Gross Profit

$312.42M

Operating Income

$206.86M

EBITDA

$221.54M

Operating Cash Flow

$128.32M

Capital Expenditure

-$20.42M

Free Cash Flow

$107.90M

Cash & ST Invst.

$138.15M

Total Debt

$204.41M

Adma Biologics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$114.49M

-0.3%

Gross Profit

$80.75M

+32.2%

Gross Margin

70.53%

N/A

Market Cap

$2.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.10M

N/A

Employees

685

N/A

Net Income

$45.33M

+68.5%

EBITDA

$61.07M

+63.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$138.15M

+92.9%

Total Debt

$204.41M

+149.2%

Accounts Receivable

$135.86M

+36.7%

Inventory

$222.10M

+29.0%

Long Term Debt

$199.95M

+147.4%

Short Term Debt

$4.46M

+275.2%

Return on Assets

24.86%

N/A

Return on Invested Capital

34.96%

N/A

Free Cash Flow

$55.71M

+328.5%

Operating Cash Flow

$58.25M

+396.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLNOSoleno Therapeutics, Inc.
$53.01+0.00%
RAREUltragenyx Pharmaceutical Inc.
$35.87+6.44%
DYNDyne Therapeutics, Inc.
$23.83+4.33%
TLXTelix Pharmaceuticals Limited
$11.74-3.37%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.20-0.03%
RIVNRivian Automotive
$16.49-0.18%
CLROClearOne
$13.84+0.98%
CRNXCrinetics Pharmaceuticals
$83.53+0.99%

Questions About ADMA

What is the current price of Adma Biologics?

Adma Biologics is trading at $9.22 per share.

What is the 52-week range for Adma Biologics?

Over the past 52 weeks, Adma Biologics has traded between $7.21 and $20.46.

How much debt does Adma Biologics have?

As of the most recent reporting period, Adma Biologics reported total debt of $204.41M.

How much cash does Adma Biologics have on hand?

Adma Biologics reported $138.15M in cash and cash equivalents in its most recent financial results.

What is Adma Biologics’s dividend yield?

Adma Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.